These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23395693)

  • 1. Efficacy of interferon-based antiviral therapy on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: further evidence in decompensation cirrhosis.
    Ji F; Zhang S; Deng H; Li Z
    J Hepatol; 2013 Jun; 58(6):1262-4. PubMed ID: 23395693
    [No Abstract]   [Full Text] [Related]  

  • 2. Lower incidence of hepatocellular carcinoma in patients with transient virologic response to peginterferon and ribavirin combination therapy: is it really the effect of the therapy?
    Toyoda H; Kumada T; Tada T
    J Hepatol; 2013 Apr; 58(4):838-9. PubMed ID: 23207142
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to: "Lower incidence of hepatocellular carcinoma in patients with transient virologic response to peginterferon and ribavirin combination therapy: is it really the effect of the therapy?".
    Ogawa E; Furusyo N; Hayashi J;
    J Hepatol; 2013 Apr; 58(4):839-40. PubMed ID: 23211318
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effectiveness of long-acting interferon (peginterferon)].
    Kondo Y; Tateishi R; Yoshida H; Omata M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):515-8. PubMed ID: 15359853
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study.
    Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Maruyama T; Tanabe Y; Satoh T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Mar; 58(3):495-501. PubMed ID: 23099187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antiviral treatments during cirrhosis].
    Bronowicki JP
    Gastroenterol Clin Biol; 2006; 30(6-7):899-902. PubMed ID: 16885876
    [No Abstract]   [Full Text] [Related]  

  • 7. The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients.
    Huang JF; Yeh ML; Yu ML; Dai CY; Huang CF; Huang CI; Tsai PC; Lin PC; Chen YL; Chang WT; Hou NJ; Lin ZY; Chen SC; Chuang WL
    J Gastroenterol Hepatol; 2015 Dec; 30(12):1768-74. PubMed ID: 26094738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.
    Bruix J; Poynard T; Colombo M; Schiff E; Burak K; Heathcote EJ; Berg T; Poo JL; Mello CB; Guenther R; Niederau C; Terg R; Bedossa P; Boparai N; Griffel LH; Burroughs M; Brass CA; Albrecht JK;
    Gastroenterology; 2011 Jun; 140(7):1990-9. PubMed ID: 21419770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.
    Jung CH; Um SH; Kim TH; Yim SY; Suh SJ; Yim HJ; Seo YS; Choi HS; Chun HJ
    Gut Liver; 2016 Sep; 10(5):808-17. PubMed ID: 27114417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of interferon-alpha for chronic hepatitis C.
    Moriyama M; Arakawa Y
    Expert Opin Pharmacother; 2006 Jun; 7(9):1163-79. PubMed ID: 16732703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HCV-HBV infection].
    Imamura M; Chayama K
    Nihon Rinsho; 2006 Jul; 64(7):1310-3. PubMed ID: 16838649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C.
    Honda T; Ishigami M; Masuda H; Ishizu Y; Kuzuya T; Hayashi K; Itoh A; Hirooka Y; Nakano I; Ishikawa T; Urano F; Yoshioka K; Toyoda H; Kumada T; Katano Y; Goto H
    J Gastroenterol Hepatol; 2015 Feb; 30(2):321-8. PubMed ID: 25091027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial.
    Huang JF; Yu ML; Huang CF; Chiu CF; Dai CY; Huang CI; Yeh ML; Yang JF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Wang LY; Chuang WL
    J Hepatol; 2011 Feb; 54(2):219-26. PubMed ID: 21056500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which is the real efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in HCV infected patients with advanced fibrosis?
    Pellicelli AM; Romano M; Guarascio P; Vignally P
    J Hepatol; 2012 Sep; 57(3):704-5. PubMed ID: 22510262
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
    Harada N; Hiramatsu N; Oze T; Tatsumi T; Hayashi N; Takehara T
    J Med Virol; 2015 Jul; 87(7):1199-206. PubMed ID: 25772024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One step forward in understanding the differences in antiviral response to interferon a2a and a2b in chronic hepatitis C patients with advanced fibrosis.
    Shouval D
    J Hepatol; 2012 Feb; 56(2):303-4. PubMed ID: 22015961
    [No Abstract]   [Full Text] [Related]  

  • 18. Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV.
    Rivero-Juarez A; Lopez-Cortes LF; Girón-Gonzalez JA; Pineda JA; Rivero A;
    Lancet Infect Dis; 2014 Jan; 14(1):13-14. PubMed ID: 24355031
    [No Abstract]   [Full Text] [Related]  

  • 19. The "pegylated" story continues--perhaps because both ends (α2a and α2b) are true?
    Reiberger T; Peck-Radosavljevic M
    J Hepatol; 2012 Jul; 57(1):226-8; author reply 229. PubMed ID: 22390901
    [No Abstract]   [Full Text] [Related]  

  • 20. [Programs for continuing medical education: a session; 2. Current therapy for chronic hepatitis C].
    Imamura M; Chayama K
    Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):625-9. PubMed ID: 24796128
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.